A detailed history of Knights Of Columbus Asset Advisors LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Knights Of Columbus Asset Advisors LLC holds 13,210 shares of HALO stock, worth $697,488. This represents 0.05% of its overall portfolio holdings.

Number of Shares
13,210
Previous 96,433 86.3%
Holding current value
$697,488
Previous $5.05 Million 85.05%
% of portfolio
0.05%
Previous 0.34%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$51.3 - $64.42 $4.27 Million - $5.36 Million
-83,223 Reduced 86.3%
13,210 $755,000
Q2 2024

Jul 30, 2024

BUY
$37.81 - $52.4 $41,817 - $57,954
1,106 Added 1.16%
96,433 $5.05 Million
Q1 2024

May 10, 2024

SELL
$33.68 - $41.95 $3.05 Million - $3.8 Million
-90,518 Reduced 48.71%
95,327 $3.88 Million
Q4 2023

Jan 31, 2024

BUY
$33.32 - $42.1 $3.08 Million - $3.9 Million
92,552 Added 99.21%
185,845 $6.87 Million
Q3 2023

Nov 01, 2023

BUY
$36.46 - $44.03 $486,813 - $587,888
13,352 Added 16.7%
93,293 $3.56 Million
Q2 2023

Jul 31, 2023

BUY
$30.28 - $38.74 $5,904 - $7,554
195 Added 0.24%
79,941 $2.88 Million
Q1 2023

May 01, 2023

BUY
$32.86 - $55.7 $165,581 - $280,672
5,039 Added 6.75%
79,746 $3.05 Million
Q4 2022

Jan 31, 2023

SELL
$40.06 - $59.44 $639,077 - $948,246
-15,953 Reduced 17.6%
74,707 $4.25 Million
Q3 2022

Nov 10, 2022

BUY
$38.53 - $51.78 $265,972 - $357,437
6,903 Added 8.24%
90,660 $3.59 Million
Q2 2022

Aug 12, 2022

BUY
$37.35 - $48.3 $1.21 Million - $1.56 Million
32,355 Added 62.95%
83,757 $3.69 Million
Q1 2022

May 16, 2022

BUY
$31.97 - $41.06 $18,830 - $24,184
589 Added 1.16%
51,402 $2.05 Million
Q4 2021

Feb 11, 2022

BUY
$31.82 - $40.75 $26,474 - $33,904
832 Added 1.66%
50,813 $2.04 Million
Q3 2021

Nov 10, 2021

BUY
$38.47 - $46.42 $1.92 Million - $2.32 Million
49,981 New
49,981 $2.03 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.35B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Knights Of Columbus Asset Advisors LLC Portfolio

Follow Knights Of Columbus Asset Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Knights Of Columbus Asset Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Knights Of Columbus Asset Advisors LLC with notifications on news.